(EXPO) Exponent - Overview
Stock: Consulting, Analysis, Testing, Risk
| Risk 5d forecast | |
|---|---|
| Volatility | 36.7% |
| Relative Tail Risk | -10.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.97 |
| Alpha | -35.78 |
| Character TTM | |
|---|---|
| Beta | 0.649 |
| Beta Downside | 0.234 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.55% |
| CAGR/Max DD | -0.33 |
EPS (Earnings per Share)
Revenue
Description: EXPO Exponent January 11, 2026
Exponent, Inc. (NASDAQ: EXPO) is a science- and engineering-consulting firm that serves a broad spectrum of industries through two operating segments: Engineering & Other Scientific, and Environmental & Health.
The Engineering segment delivers expertise in biomechanics, biomedical engineering, civil/structural engineering, data science, electrical/computer engineering, materials science, mechanical engineering, polymer chemistry, thermal sciences, and vehicle engineering. The Environmental & Health segment focuses on chemical regulation, food safety, ecological and biological sciences, environmental and earth sciences, and health sciences, plus proactive/reactive product safety, litigation support, and regulatory services.
Key customers span chemicals, construction, consumer products, energy, food & beverage, government, life sciences, insurance, manufacturing, technology, industrial equipment, and transportation, reflecting the firm’s diversified revenue base.
Recent performance highlights (FY 2023) include revenue of approximately $1.0 billion, an operating margin near 13 %, and a backlog exceeding $1.2 billion, indicating strong demand for consulting services amid heightened ESG compliance and rising product-liability litigation. The sector is further buoyed by increased regulatory scrutiny in chemicals and food safety, which drives steady growth for firms with deep technical expertise.
For a deeper quantitative assessment, you might explore ValueRay’s analyst notes on EXPO.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 106.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -3.94 > 1.0 |
| NWC/Revenue: 42.88% < 20% (prev 50.80%; Δ -7.91% < -1%) |
| CFO/TA 0.17 > 3% & CFO 132.2m > Net Income 106.0m |
| Net Debt (-139.1m) to EBITDA (152.4m): -0.91 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.6m) vs 12m ago -2.03% < -2% |
| Gross Margin: 40.09% > 18% (prev 0.42%; Δ 3966 % > 0.5%) |
| Asset Turnover: 74.87% > 50% (prev 71.86%; Δ 3.01% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 7.99
| A: 0.32 (Total Current Assets 427.6m - Total Current Liabilities 178.0m) / Total Assets 777.5m |
| B: 0.86 (Retained Earnings 668.4m / Total Assets 777.5m) |
| C: 0.19 (EBIT TTM 147.3m / Avg Total Assets 777.4m) |
| D: 1.72 (Book Value of Equity 666.2m / Total Liabilities 387.2m) |
| Altman-Z'' Score: 7.99 = AAA |
Beneish M -2.85
| DSRI: 1.08 (Receivables 181.5m/161.4m, Revenue 582.0m/558.5m) |
| GMI: 1.05 (GM 40.09% / 42.15%) |
| AQI: 1.12 (AQ_t 0.26 / AQ_t-1 0.23) |
| SGI: 1.04 (Revenue 582.0m / 558.5m) |
| TATA: -0.03 (NI 106.0m - CFO 132.2m) / TA 777.5m) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of EXPO shares?
Over the past week, the price has changed by -16.29%, over one month by -8.42%, over three months by -4.10% and over the past year by -25.02%.
Is EXPO a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EXPO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.7 | 37.3% |
| Analysts Target Price | 91.7 | 37.3% |
| ValueRay Target Price | 62.3 | -6.7% |
EXPO Fundamental Data Overview February 13, 2026
P/E Forward = 34.1297
P/S = 6.7478
P/B = 9.4298
P/EG = 3.14
Revenue TTM = 582.0m USD
EBIT TTM = 147.3m USD
EBITDA TTM = 152.4m USD
Long Term Debt = 75.9m USD (estimated: total debt 82.8m - short term 6.89m)
Short Term Debt = 6.89m USD (from shortTermDebt, last quarter)
Debt = 82.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -139.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.48b USD (3.62b + Debt 82.8m - CCE 221.9m)
Interest Coverage Ratio = unknown (Ebit TTM 147.3m / Interest Expense TTM 0.0)
EV/FCF = 28.34x (Enterprise Value 3.48b / FCF TTM 122.9m)
FCF Yield = 3.53% (FCF TTM 122.9m / Enterprise Value 3.48b)
FCF Margin = 21.12% (FCF TTM 122.9m / Revenue TTM 582.0m)
Net Margin = 18.21% (Net Income TTM 106.0m / Revenue TTM 582.0m)
Gross Margin = 40.09% ((Revenue TTM 582.0m - Cost of Revenue TTM 348.7m) / Revenue TTM)
Gross Margin QoQ = 24.32% (prev 24.94%)
Tobins Q-Ratio = 4.48 (Enterprise Value 3.48b / Total Assets 777.5m)
Interest Expense / Debt = 7.75% (Interest Expense 6.42m / Debt 82.8m)
Taxrate = 27.39% (9.34m / 34.1m)
NOPAT = 106.9m (EBIT 147.3m * (1 - 27.39%))
Current Ratio = 2.40 (Total Current Assets 427.6m / Total Current Liabilities 178.0m)
Debt / Equity = 0.21 (Debt 82.8m / totalStockholderEquity, last quarter 390.3m)
Debt / EBITDA = -0.91 (Net Debt -139.1m / EBITDA 152.4m)
Debt / FCF = -1.13 (Net Debt -139.1m / FCF TTM 122.9m)
Total Stockholder Equity = 415.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.64% (Net Income 106.0m / Total Assets 777.5m)
RoE = 25.51% (Net Income TTM 106.0m / Total Stockholder Equity 415.6m)
RoCE = 29.97% (EBIT 147.3m / Capital Employed (Equity 415.6m + L.T.Debt 75.9m))
RoIC = 25.22% (NOPAT 106.9m / Invested Capital 424.0m)
WACC = 8.25% (E(3.62b)/V(3.70b) * Re(8.31%) + D(82.8m)/V(3.70b) * Rd(7.75%) * (1-Tc(0.27)))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.82%
[DCF Debug] Terminal Value 76.80% ; FCFF base≈135.1m ; Y1≈131.9m ; Y5≈132.9m
Fair Price DCF = 47.68 (EV 2.24b - Net Debt -139.1m = Equity 2.38b / Shares 49.9m; r=8.25% [WACC]; 5y FCF grow -3.46% → 2.90% )
EPS Correlation: 6.36 | EPS CAGR: -3.50% | SUE: 0.32 | # QB: 0
Revenue Correlation: 70.78 | Revenue CAGR: 3.69% | SUE: 2.53 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.61 | Chg30d=+0.066 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-12-31): EPS=2.45 | Chg30d=+0.223 | Revisions Net=+2 | Growth EPS=+18.5% | Growth Revenue=+10.4%
EPS next Year (2027-12-31): EPS=2.71 | Chg30d=+0.302 | Revisions Net=+0 | Growth EPS=+10.6% | Growth Revenue=+8.0%